Floatz logo

Bicalutamide

Secondary Malignant Neoplasm

Gynaecologisch Oncologisch Centrum ZuidSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Secondary Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
Oxaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Capecitabine
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Sacubitril Valsartan
Silesian Centre for Heart Diseases
Phase 4BB
Irinotecan
Ludwig-Maximilians - University of Munich
Phase 2BB
Letrozole
Gynaecologisch Oncologisch Centrum Zuid
Phase 2/3B

View all 21 →

Same molecule, other indications

Bicalutamide is also rated in:

prostate adenocarcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →